• Subscribe
  • Magazine
  • Videos
  • Advertise
  • About Us
  • Smart Water Summit
  • Wastewater Summit
    • Recent Quotes
    My Watchlist
    Indicators
    WaterWorld Market Index
    Markets
    Stocks
    ETFs
    Tools
    Markets:
    Overview
    News
    Currencies
    International
    Treasuries

    Syndax Pharmaceuticals, Inc. - Common Stock (NQ:SNDX)

    13.71 -2.84 (-17.16%)
    Delayed Quote Updated: 2:42 PM EDT, Oct 13, 2026 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Price and Volume

    Detailed Quote
    Volume 4,968,701
    Open 14.61
    Bid (Size) 13.70 (100)
    Ask (Size) 13.72 (100)
    Prev. Close 16.55
    Today's Range 13.49 - 14.74
    52wk Range 12.99 - 25.59
    Shares Outstanding 69,484,053
    Dividend Yield N/A
    Chart for (: )
    Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

    Top News

    More News
    What's going on in today's after hours session ↗
    Via Chartmill
    News headline image
    Syndax Announces Topline Results from MAXPIRe Phase 2 Trial of Axatilimab in Idiopathic Pulmonary Fibrosis
    From Syndax Pharmaceuticals, Inc.
    Via GlobeNewswire

    Performance

    52-Week Range 46.4% below 52-week high
    13.71
    12.9952W Low 25.5952W High
    1 Week 24.6% below 1-week high
    16.371W Low 18.191W High

    Syndax Pharmaceuticals, Inc. - Common Stock (SNDX) traded between $12.99 and $25.59 over the past 52 weeks and last traded at $13.71, 46.4% below its 52-week high. Over the past week it ranged between $16.37 and $18.19.

    Past 12 Months
    -21.1%
    -25.3%
    -40.1%
    -43.5%
    -35.6%
    -9.8%
    1W -$3.66
    1M -$4.64
    3M -$9.18
    6M -$10.54
    YTD -$7.59
    1Y -$1.49

    SNDX was -9.8% over the past year, -43.5% over six months, -35.6% year to date, -21.1% in the last week.

    12 Months vs Market
    SNDX
    -9.8%
    DIA
    +12.2%
    SPY
    +17.3%
    QQQ
    +23.3%
    IWM
    +13.3%

    Over the past 12 months SNDX returned -9.8% versus DIA (Dow) +12.2%, SPY (S&P 500) +17.3%, QQQ (Nasdaq 100) +23.3% and IWM (Russell 2000) +13.3%.

    Volume & Liquidity 3.20× 3-mo avg
    Today 4,968,701 3-mo avg 1.6M
    1W
    1.7M
    1M
    1.9M
    3M
    1.6M
    6M
    1.7M
    YTD
    1.6M
    1Y
    1.8M

    SNDX most recently traded 4,968,701 shares against a 3-month average daily volume of 1.6M.

    More News

    Read More
    News headline image
    Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
    From Syndax Pharmaceuticals, Inc.
    Via GlobeNewswire
    News headline image
    Syndax Announces Participation in September Investor Conferences
    From Syndax Pharmaceuticals, Inc.
    Via GlobeNewswire
    Syndax Pharmaceuticals (NASDAQ:SNDX) Shares Drop as Q2 Revenue and EPS Miss Estimates ↗
    Via Chartmill
    Syndax Pharmaceuticals Inc (NASDAQ:SNDX) Stock Slides After Q1 Revenue Misses Street Forecasts Despite 224% Growth ↗
    Via Chartmill
    News headline image
    Syndax (SNDX) Q2 2026 Earnings Call Transcript ↗
    Via The Motley Fool
    Topics Earnings
    News headline image
    Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
    From Syndax Pharmaceuticals, Inc.
    Via GlobeNewswire
    News headline image
    Syndax Pharmaceuticals Q2 Earnings Call Highlights ↗
    Via MarketBeat
    Topics Earnings
    News headline image
    Syndax Reports Second Quarter 2026 Financial Results and Provides Business Update
    From Syndax Pharmaceuticals, Inc.
    Via GlobeNewswire
    News headline image
    Syndax to Announce Second Quarter 2026 Financial Results and Host Conference Call and Webcast on August 4, 2026
    From Syndax Pharmaceuticals, Inc.
    Via GlobeNewswire
    News headline image
    Syndax Pharmaceuticals Maps Growth Beyond Revuforj With Lung Cancer, Myelofibrosis Push ↗
    Via MarketBeat
    News headline image
    Syndax to Highlight Late-Stage Programs and Unveil New Pipeline Assets at R&D Event
    From Syndax Pharmaceuticals, Inc.
    Via GlobeNewswire
    News headline image
    Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
    From Syndax Pharmaceuticals, Inc.
    Via GlobeNewswire
    News headline image
    Syndax Showcases Revuforj® (revumenib) Clinical Activity in Multiple Acute Leukemia Subtypes and Settings at EHA 2026
    From Syndax Pharmaceuticals, Inc.
    Via GlobeNewswire
    News headline image
    Syndax Announces Publication of SAVE Data on Revuforj® (revumenib) in Combination with Decitabine/Cedazuridine and Venetoclax in Relapsed/Refractory NPM1m, KMT2Ar, and NUP98r AML in the Journal of Clinical Oncology
    From Syndax Pharmaceuticals, Inc.
    Via GlobeNewswire
    News headline image
    Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
    From Syndax Pharmaceuticals, Inc.
    Via GlobeNewswire
    News headline image
    Syndax Announces Private Placement of $250.0 Million of Convertible Senior Notes
    From Syndax Pharmaceuticals, Inc.
    Via GlobeNewswire
    News headline image
    Syndax Highlights Revuforj® (revumenib) Data Presented at ASCO 2026, Including an Oral Presentation of Post-Transplant Data
    From Syndax Pharmaceuticals, Inc.
    Via GlobeNewswire
    News headline image
    Syndax to Host R&D Day Highlighting its Late-Stage Programs and Early-Stage Assets on July 14, 2026
    From Syndax Pharmaceuticals, Inc.
    Via GlobeNewswire
    News headline image
    Syndax Announces Four Revuforj® (revumenib) Abstracts Accepted for ASCO 2026, Including an Oral Presentation of Post-Transplant Data
    From Syndax Pharmaceuticals, Inc.
    Via GlobeNewswire
    News headline image
    Syndax Announces Participation in Upcoming Investor Conferences
    From Syndax Pharmaceuticals, Inc.
    Via GlobeNewswire
    News headline image
    Syndax Highlights 12 Revuforj® (revumenib) Abstracts Accepted for EHA 2026, Advancing Leadership in Menin Inhibition
    From Syndax Pharmaceuticals, Inc.
    Via GlobeNewswire
    News headline image
    Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
    From Syndax Pharmaceuticals, Inc.
    Via GlobeNewswire
    News headline image
    Syndax Reports First Quarter 2026 Financial Results and Provides Business Update
    From Syndax Pharmaceuticals, Inc.
    Via GlobeNewswire

    Frequently Asked Questions

    Is Syndax Pharmaceuticals, Inc. - Common Stock publicly traded?
    Yes, Syndax Pharmaceuticals, Inc. - Common Stock is publicly traded.
    What exchange does Syndax Pharmaceuticals, Inc. - Common Stock trade on?
    Syndax Pharmaceuticals, Inc. - Common Stock trades on the Nasdaq Stock Market
    What is the ticker symbol for Syndax Pharmaceuticals, Inc. - Common Stock?
    The ticker symbol for Syndax Pharmaceuticals, Inc. - Common Stock is SNDX on the Nasdaq Stock Market
    What is the current price of Syndax Pharmaceuticals, Inc. - Common Stock?
    The current price of Syndax Pharmaceuticals, Inc. - Common Stock is 13.71
    When was Syndax Pharmaceuticals, Inc. - Common Stock last traded?
    The last trade of Syndax Pharmaceuticals, Inc. - Common Stock was at 10/13/26 02:42 PM ET
    What is the market capitalization of Syndax Pharmaceuticals, Inc. - Common Stock?
    The market capitalization of Syndax Pharmaceuticals, Inc. - Common Stock is 952.63M
    How many shares of Syndax Pharmaceuticals, Inc. - Common Stock are outstanding?
    Syndax Pharmaceuticals, Inc. - Common Stock has 953M shares outstanding.
    Stock Quote API & Stock News API supplied by www.cloudquote.io
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the Privacy Policy and Terms Of Service.
    © 2025 FinancialContent. All rights reserved.